Business Wire

NY-ALIXPARTNERS

19.7.2022 15:02:14 CEST | Business Wire | Press release

Share
Global Finance Execs Predict Imminent Downturn, According to AlixPartners Survey

Global consulting firm AlixPartners today announced the findings of its 17th Annual Turnaround and Transformation Survey, which reveal that over 600 of the world’s leading finance professionals most experienced in responding to the downside of economic volatility see a period of widespread business distress looming.

  • For the first time in 50 years, the downturn will be inflation-led – with 97% predicting that inflation will be a major driver of economic stress
  • 24% anticipate a recession before the end of this calendar year, and
  • 70% see it happening in the next 12 months
  • More than half of global respondents (57%) believe the likelihood of a U.S. recession is 50% or more in the next 12 months.

Challenging financing markets and the efforts of ESG compliance
As belts tighten, companies’ chances of survival will be measured by the amount of cash sitting on their balance sheets. More than a third of survey respondents expect the majority of distressed companies that tapped the credit markets for financing in 2021 will need more in the next three years. Adding further pressure to the situation: survey respondents say that the availability of capital has decreased (44%) or remained flat (43%), and 52% say financial terms have grown more restrictive compared with 2021.

Compounding the already challenging financing markets are the efforts to comply with ESG guidelines. More than 84% of survey respondents believe a company’s ability to comply with ESG guidelines will impact its financial performance, and 69% agree that access to financing depends on ESG compliance.

Recession-driven M&A activity expected to jump
A recession will drive not just company restructurings but will lead to a new round of industry consolidation and reinvention: 76% of survey respondents believe that M&A transactions involving distressed assets will increase; 12% think that these will reach a new high. In an environment ruled by disruption and uncertainty, major corporations are attempting to stabilize enterprise value, and private equity firms are streamlining their portfolios. This environment creates opportunities for companies with the appropriate capital structure to pick up weaker players via M&A and build greater competitiveness for the long term, potentially at discounted prices. On the flip-side others are reassessing geographic areas of challenge or other cost-cutting measures and taking strategic action to prune portfolios and corporate structures. Would-be buyers and sellers alike are facing renewed pressure from investors and boards to focus on their core businesses to drive growth in the face of disruption. It remains to be seen where the best deals lie and who will benefit the most, but it’s clear that our respondents see a busy market on the horizon.

These findings are based on a survey conducted in May 2022 of over 600 senior experts from investment banks, lenders, financial advisory firms, law firms and corporate professionals across 20 industries based in the US, UK, Europe, Middle East and Africa, and Asia. The full report, “Preparing for the Storm” can be viewed at: alixpartners.com/storm.

Joff Mitchell, global co-lead of the firm’s Turnaround & Restructuring Services practice, said: “Business leaders must brace for further uncertainty in the realm of geopolitics, interest rates, and inflation. Growth can no longer be fuelled by cheap money, and business models have to be supported by profits. The winners will be those leadership teams who can transform their businesses with pace, agility, foresight, and an action-oriented point of view to navigate the choppy waters ahead. If a ‘turnaround mindset’ proved to be a defining factor in establishing a competitive edge during the height of the pandemic, it must now be locked in to effectively tackle a new and even bigger wave of market volatility.”

Jim Mesterharm, global co-lead of the firm’s Turnaround & Restructuring Services practice, said: “The finance experts who responded to our survey have borne out the stark reality — that the day of recession reckoning is upon us. While no one can pick the precise timing, our respondents tell us we are heading for a global recession and another intense period of restructuring. Companies unable to refinance because new funding is not available or because it's too expensive, are going to be at the forefront of this. If your runway is less than a year, then you’re heading for panic mode, assuming you’re not in it already.”

About AlixPartners
AlixPartners is a results-driven global consulting firm that specializes in helping businesses successfully address their most complex and critical challenges. Our clients include companies, corporate boards, law firms, investment banks, private equity firms, and others. Founded in 1981, AlixPartners is headquartered in New York and has offices in more than 20 cities around the world. For more information, visit www.alixpartners.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye